PMN

Patrick D. Kirwin

Known title: DirectorCIK: 0001927062

Patrick D. Kirwin's purchase track record

How the stock did after each of Patrick D. Kirwin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 4 since August 17, 2022
Stock higher 6 months later
0%
3 months: 50%
Median 6-month return
-14.7%
3 months: -3.8%
Beat the S&P 500
0%
median -11.7% vs. index
PurchaseStockAmount3 months6 months
4/22/2026PMN$45K+25.9%pending
8/14/2024PMN$12K-19.0%-24.8%
12/9/2022PMN$19K-10.0%-0.6%
8/17/2022PMN$24K+2.4%-14.7%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer. ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.

this person other insiders at PMN

Transaction History

PMN▲ Buy$45K
PMN▲ Buy$37K
PMN▲ Buy$12K
PMN▲ Buy—
PMN▲ Buy$9K
PMN▲ Buy$5K
PMN▲ Buy$5K
PMN▲ Buy$24K

We use analytics to understand how market-wall is used. No personal data is sold.